CN115531424A - Probiotic drops - Google Patents
Probiotic drops Download PDFInfo
- Publication number
- CN115531424A CN115531424A CN202110759489.0A CN202110759489A CN115531424A CN 115531424 A CN115531424 A CN 115531424A CN 202110759489 A CN202110759489 A CN 202110759489A CN 115531424 A CN115531424 A CN 115531424A
- Authority
- CN
- China
- Prior art keywords
- probiotic
- drops
- lactobacillus
- drop
- spp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 88
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 88
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 68
- 241000894006 Bacteria Species 0.000 claims abstract description 38
- 239000004006 olive oil Substances 0.000 claims abstract description 22
- 235000008390 olive oil Nutrition 0.000 claims abstract description 22
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000003921 oil Substances 0.000 claims abstract description 10
- 235000019198 oils Nutrition 0.000 claims abstract description 10
- 235000020238 sunflower seed Nutrition 0.000 claims abstract description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 24
- 235000019486 Sunflower oil Nutrition 0.000 claims description 16
- 239000002600 sunflower oil Substances 0.000 claims description 16
- 229930006000 Sucrose Natural products 0.000 claims description 14
- 239000005720 sucrose Substances 0.000 claims description 14
- 241000186660 Lactobacillus Species 0.000 claims description 12
- 229930003427 Vitamin E Natural products 0.000 claims description 12
- 239000002274 desiccant Substances 0.000 claims description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 12
- 235000019165 vitamin E Nutrition 0.000 claims description 12
- 229940046009 vitamin E Drugs 0.000 claims description 12
- 239000011709 vitamin E Substances 0.000 claims description 12
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 10
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 9
- 229940039696 lactobacillus Drugs 0.000 claims description 9
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 8
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 8
- 241000186000 Bifidobacterium Species 0.000 claims description 7
- 241000194033 Enterococcus Species 0.000 claims description 6
- 241000194036 Lactococcus Species 0.000 claims description 6
- 241000192001 Pediococcus Species 0.000 claims description 6
- 241000194017 Streptococcus Species 0.000 claims description 6
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 5
- 241000192132 Leuconostoc Species 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 description 19
- 238000003860 storage Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- -1 alcohol ester Chemical class 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- 239000008158 vegetable oil Substances 0.000 description 5
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 241001608472 Bifidobacterium longum Species 0.000 description 3
- 240000002605 Lactobacillus helveticus Species 0.000 description 3
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 3
- 240000006024 Lactobacillus plantarum Species 0.000 description 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 3
- 241000186604 Lactobacillus reuteri Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229940009291 bifidobacterium longum Drugs 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 229940054346 lactobacillus helveticus Drugs 0.000 description 3
- 229940072205 lactobacillus plantarum Drugs 0.000 description 3
- 229940001882 lactobacillus reuteri Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241000186012 Bifidobacterium breve Species 0.000 description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 2
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 description 2
- 241000186605 Lactobacillus paracasei Species 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 229940004120 bifidobacterium infantis Drugs 0.000 description 2
- 229940009289 bifidobacterium lactis Drugs 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 229920000223 polyglycerol Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000185999 Bifidobacterium longum subsp. longum Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 244000000036 gastrointestinal pathogen Species 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Edible Oils And Fats (AREA)
Abstract
The present invention relates to probiotic drops. The invention discloses a probiotic drop, wherein the drop comprises the following components by weight based on the total weight of the drop: 1-15wt% of probiotic bacteria; 31-50wt% sunflower seed oil; 31-50wt% olive oil; and 17-30wt% of triglyceride.
Description
Technical Field
The invention relates to a probiotic drop (probiotic drop), wherein the drop comprises, based on the total weight of the drop: 1-15wt% of probiotic bacteria; 31-50wt% sunflower oil (sunflower oil); 31-50wt% olive oil (olive oil); and 17-30wt% of triglyceride (triglyceride).
Background
Probiotics selectively stimulate the growth of native bacteria (native bacteria) in the gut, alter the composition, quantity or nature of the gut microbiota (intestinal microflora), and when administered in appropriate amounts, confer a health benefit (health benefit) to the host. Microorganisms currently known for use as probiotics include: species such as Lactobacillus, lactococcus, pediococcus, enterococcus, streptococcus, bifidobacterium, bacillus, and Leuconostoc.
Many studies have shown that probiotics have the effects of inhibiting the growth of gastrointestinal pathogens, alleviating lactose intolerance (lactose intemperance), preventing and/or treating gastrointestinal diseases (gastrointestinal disease), immunomodulation (immunomodulation), anti-bacterial (anti-bacterial), anti-cancer (anti-cancer) and blood pressure lowering (anti-hypertension).
However, during the preparation of probiotic preparations (probiotic preparations), the survival time of the probiotics in the probiotic preparations is affected by the type of the selected preparation formulation and the storage environment (e.g., temperature and humidity), and thus the number of bacteria required for the probiotics preparation to exert effect cannot be maintained. Therefore, how to maintain the number of probiotics in the probiotic preparation has become an objective of the relevant researchers in this field.
In recent years, researchers of interest have attempted to increase the survival rate of probiotics by dispersing the probiotics in lipid solvents. For example, CN 105707897A discloses a probiotic lipid suspension drop, which comprises probiotic powder, vegetable oil, medium chain glyceride (medium chain glyceride), sucrose monoglyceride (sucrose monoglyceride) and vitamin E (vitamin E). In the example of this piece of chinese patent publication, sunflower oil (sunflower oil) was used to formulate lipid suspension drops of Lactobacillus reuteri and Lactobacillus plantarum, respectively, and demonstrate that the bacterial count of the probiotic bacteria could be maintained.
Despite the above-mentioned reports, there is still a need in the art to develop a probiotic preparation that can effectively improve the stability of probiotics for industrial needs.
Disclosure of Invention
In the present invention, the applicant found that a probiotic drop (probiotic drop) containing probiotics, sunflower oil (sunflower oil), olive oil (olive oil) and triglyceride (triglyceride) can effectively improve the stability of the probiotics, and further can maintain the activity of the probiotics under long-term storage.
Accordingly, the present invention provides a probiotic drop wherein the drop comprises, based on the total weight of the drop:
1-15wt% of probiotic bacteria;
31-50wt% sunflower seed oil;
31-50wt% olive oil; and
17-30wt% of triglyceride.
Preferably, the sunflower oil is present in substantially the same amount as olive oil.
Preferably, the drop further comprises: 0.1-1.5wt% sucrose monoglyceride; and 0.01-0.05wt% of vitamin E.
Preferably, the probiotic is selected from the group consisting of: lactobacillus species (Lactobacillus spp.), lactococcus species (Lactococcus spp.), pediococcus species (Pediococcus spp.), enterococcus species (Enterococcus spp.), streptococcus species (Streptococcus spp.), bifidobacterium species (Bifidobacterium spp.), bacillus spp., leuconostoc spp., and combinations thereof.
More preferably, the probiotic is selected from the group consisting of: lactobacillus rhamnosus (Lactobacillus), bifidobacterium animalis subsp.
Preferably, the drop further comprises a desiccant.
Drawings
The above and other objects, features and advantages of the present invention will become apparent upon consideration of the following detailed description and preferred embodiments thereof, taken in conjunction with the accompanying drawings, in which:
FIG. 1 shows the bacterial concentration of various drops containing Lactobacillus rhamnosus MP108 as a function of time when stored at 37 ℃ wherein drops 1 to 7 have a formulation as shown in Table 2 below; and
figure 2 shows the bacterial concentration of various drops containing bifidobacterium animalis subsp lactis CP-9 as a function of time when stored at 37 c, where drops 1 to 7 generally have a formulation as shown in table 2 below, with the difference that: the bacterial powder of bifidobacterium animalis subsp lactis CP-9 is used for replacing the bacterial powder of lactobacillus rhamnosus MP108.
Detailed Description
For the purposes of this specification, it will be clearly understood that: the word "comprising" means "including but not limited to", and the word "comprising" has a corresponding meaning.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which can be used in the practice of the present invention. Of course, the present invention is in no way limited to the methods and materials described.
The present invention provides a probiotic drop (probiotic drop), wherein the drop comprises, based on the total weight of the drop:
1-15wt% of probiotic bacteria;
31-50wt% sunflower oil (sunflower oil);
31-50wt% olive oil (olive oil); and
17-30wt% of triglyceride (triglyceride).
According to the invention, the sunflower oil has substantially the same content as olive oil.
As used herein, the term "substantially identical" means having equal amounts (equivalents) or differing by less than 1.5 wt%. Preferably, the sunflower seed oil has exactly the same content as the olive oil.
According to the invention, the drops have a concentration of bacteria in the range of 8.5 to 10.6log CFU/mL of probiotic bacteria. In a preferred embodiment of the invention, the drops have a concentration of bacteria of 10.4log CFU/mL of probiotic bacteria. In another preferred embodiment of the invention, the drops have a concentration of bacteria of 10.6log CFU/mL.
According to the invention, the probiotic bacteria may be natural materials or processed products (e.g. freeze-dried or spray-dried products). Preferably, the probiotic is a processed product. More preferably, the probiotic is a powder of bacteria obtained by freeze-drying followed by grinding.
According to the invention, the probiotic may be selected from the group consisting of: lactobacillus species (Lactobacillus spp.), lactococcus species (Lactococcus spp.), pediococcus species (Pediococcus spp.), enterococcus species (Enterococcus spp.), streptococcus species (Streptococcus spp.), bifidobacterium species (Bifidobacterium spp.), bacillus spp., leuconostoc spp., and combinations thereof.
Preferably, the probiotic is a lactobacillus species selected from the group consisting of: lactobacillus rhamnosus (Lactobacillus rhamnous), lactobacillus plantarum (Lactobacillus plantarum), lactobacillus acidophilus (Lactobacillus acidophilus), lactobacillus casei (Lactobacillus casei), lactobacillus paracasei (Lactobacillus paracasei), lactobacillus reuteri (Lactobacillus reuteri), lactobacillus bulgaricus (Lactobacillus bulgaricus), dai Baishi Lactobacillus delbrueckii), lactobacillus johnsonii (Lactobacillus johnsonii), lactobacillus helveticus (Lactobacillus helveticus), lactobacillus gasseri (Lactobacillus helveticus), lactobacillus fermentum (Lactobacillus fermentum), and combinations thereof. In a preferred embodiment of the invention, the probiotic is lactobacillus rhamnosus MP108.
Preferably, the probiotic is a bifidobacterium species selected from the group consisting of: bifidobacterium animalis subsp. lactis, bifidobacterium bifidum (Bifidobacterium bifidum), bifidobacterium lactis (Bifidobacterium lactis), bifidobacterium longum (Bifidobacterium longum) [ e.g., bifidobacterium longum (Bifidobacterium longum subsp. Longum) ], bifidobacterium breve (Bifidobacterium breve), bifidobacterium adolescentis (Bifidobacterium adolescentis), bifidobacterium infantis (Bifidobacterium infantis), and combinations thereof. In a preferred embodiment of the invention, the probiotic is Bifidobacterium animalis subsp lactis CP-9.
Alternatively, the probiotic may also be selected from the group consisting of: lactococcus lactis (Lactococcus lactis), streptococcus thermophilus (Streptococcus thermophilus), bacillus coagulans (Bacillus coagulousns), and combinations thereof.
According to the invention, the drop further comprises, based on the total weight of the drop:
0.1-1.5wt% of alcohol ester emulsifier (alcohol ester type emulsifying agent); and
0.01-0.05wt% of vitamin E (vitamin E).
Preferably, the alcohol ester emulsifier is selected from the group consisting of: sucrose glyceride (sucrose), polysorbate 80 (polysorbate 80), polyglycerol fatty acid esters (polyglycerol fatty acid esters), and combinations thereof. In a preferred embodiment of the present invention, the alcohol ester emulsifier is sucrose monoglyceride (sucrose).
According to the present invention, the drop may further comprise a drying agent (desiccant).
The desiccants suitable for use in the present invention may be commercially available products including, but not limited to: a dry TABLET (obtained from Aptar CSP Technologies under the product model number M-3061-133ACTIVE TABLET) and a dry film (obtained from CSP Technologies under the product model number M-0026 ACTIVE-Strip) TM )。
According to the invention, the drops may further comprise other pharmaceutically acceptable additives (additives) which are widely used in pharmaceutical manufacturing technology, such as preservatives (preservative), antioxidants (antioxidant), absorption enhancers (absorption enhancer) and stabilisers (stabilizing agent). The selection and amounts of such additives are within the skill and routine skill of those skilled in the art.
In a preferred embodiment of the invention, the drops comprise, based on the total weight of the drops: 7wt% of probiotics, 31.94wt% of sunflower oil, 31.94wt% of olive oil, 28.9wt% of triglyceride, 0.2wt% of sucrose monoglyceride and 0.02wt% of vitamin E.
In another preferred embodiment of the invention, the drops comprise, based on the total weight of the drops: 7wt% probiotics, 47.94wt% sunflower oil, 15.94wt% olive oil, 28.9wt% triglycerides, 0.2wt% sucrose monoglyceride and 0.02wt% vitamin E.
In yet another preferred embodiment of the invention, the drops comprise, based on the total weight of the drops: 7wt% probiotic bacteria, 15.94wt% sunflower oil, 47.94wt% olive oil, 28.9wt% triglycerides, 0.2wt% sucrose monoglyceride and 0.02wt% vitamin E.
The probiotic drops according to the invention may be administered orally (orally) in a single dose or in divided doses.
The invention will be further described with respect to the following examples, but it should be understood that these examples are for illustrative purposes only and should not be construed as limiting the practice of the invention.
< example >
General experimental materials:
1. probiotic bacterial strains:
the probiotic strains used in the following examples for efficacy evaluation have been deposited at the Center for biological resource conservation and Research Center (BCRC) of Food Industry Research and Development Institute (FIRDI) in taiwan, food Industry, research and Development Institute (300 new bamboo Food road 331, taiwan), and are publicly available. In addition, the probiotic strains are also deposited in the German Collection of microorganisms (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, DSMZ) and the Chinese Collection of Type cultures (CCTCC), respectively, according to the Budapest Treaty. For clarity, the information (including the academic name, the related origin, the accession number and the accession date) of each probiotic strain is integrated in the following Table 1.
TABLE 1 information on individual probiotic strains
2. Preparation of bacterial powders of various probiotic strains:
first, 2 probiotic strains described in item 1 above were inoculated into MRS broth (MRS broth) supplemented with 0.05% cysteine (cysteine), respectively, and cultured at 37 ℃ for 24 hours to activate the strains. Then, the activated strains were inoculated in MRS broth at an inoculum size of 2% (v/v), respectively, and cultured under an anaerobic condition at 37 ℃ over night. The resulting cultures were centrifuged at 3,000rpm for 10 minutes at 4 ℃ after counting the number of bacteria in a plate counting medium, followed by removal of the supernatant, and the resulting pellets (pellets) were each taken to mix with a freeze-drying protecting agent (freeze-drying protecting agent). Then, the resulting mixture was put in a liquid nitrogen bucket at-196 ℃ for quick freezing, and then dried. Then, the mixture was ground by a pulverizer (model number Comil U20, manufactured by Quadro) and then sieved by a 40-mesh sieve, thereby obtaining powders of Lactobacillus rhamnosus MP108 and Bifidobacterium animalis subsp.lactis CP-9 (each having 5.7X 10. Sup. Times. 10. Sup. Respectively) 11 CFU/g and 3.7X 10 11 Bacterial concentration of CFU/g).
3. The 3 vegetable oils sunflower oil (sunflower oil), olive oil (olive oil) and peanut oil (peanout oil) used in the examples below were obtained from Yu Guige food, soy and Taishan industries, respectively.
4. The triglycerides (triglycerides), sucrose monoglycerides (sucrose esters) and vitamin E (vitamin E) used in the examples below were obtained from Yuba corporation, zhengxing food additives, and Xinjiang corporation, respectively.
Example 1 preparation of drops (drop) containing probiotic bacteria
In this example, the applicant prepared 7 drops containing lactobacillus rhamnosus MP108 (i.e. drop 1 to drop 7 of MP 108) according to the formulation shown in table 2 below. The preparation method of various drops is carried out according to the following steps: first, vegetable oil, triglyceride, sucrose monoglyceride and vitamin E were mixed and stirred until emulsification (emulisification), then bacterial powder was slowly added and stirred well to obtain drops containing probiotic bacteria (bacteria concentration of 10.6log CFU/mL), each drop having a volume of 8mL and a total weight of 7.6g.
TABLE 2 formulation of drops containing probiotics
In addition, 7 drops containing Bifidobacterium animalis Lactobacillus subsp CP-9 (i.e., drops 1 to 7 of CP-9) were prepared substantially according to the formulation shown in Table 2 above, except that: the bacterial powder of bifidobacterium animalis subsp lactis CP-9 is used for replacing the bacterial powder of lactobacillus rhamnosus MP108, and the drops contain probiotics with the bacterial concentration of 10.4log CFU/mL.
Example 2 Effect of probiotic-containing drops made with different vegetable oils on probiotic stability
In this example, in order to investigate the effectiveness of probiotic containing drops prepared using different vegetable oils in improving the stability of probiotics, the applicant carried out stability tests (stability test) on 14 probiotic containing drops obtained according to example 1 above.
The experimental method comprises the following steps:
the 14 probiotic bacteria-containing drops were stored in a constant temperature and humidity chamber (ATH-120, available from grand precision industries, ltd.) for 28 days at a temperature set at 37 ℃, and 2mL of each of the 14 probiotic bacteria-containing drops were diluted before starting storage (i.e., day 0) and at 14 and 28 days after starting storage by adding 18mL of 0.1% peptone diluent (available from Merck), followed by counting the number of bacteria in a plate count medium.
As a result:
figure 1 shows the bacterial concentration of various drops containing lactobacillus rhamnosus MP108 as a function of time when stored at 37 ℃. As can be seen from fig. 1, the number of bacteria contained in drops 1 to 7 gradually decreases with increasing storage time, wherein the number of bacteria contained in drops 3, 4 and 5 decreases by a significantly smaller amount than those contained in drops 1, 2, 6 and 7. In particular, the bacterial concentration of drops 3, 4 and 5 was also maintained above 8.5log CFU/mL after 28 days of storage, with the highest bacterial concentration of drops 3.
Figure 2 shows the bacterial concentration of various drops containing Bifidobacterium animalis Lactobacillus subsp CP-9 as a function of time when stored at 37 ℃. As can be seen from fig. 2, the number of bacteria contained in drops 1, 2, 6 and 7 decreased with increasing storage time, whereas the number of bacteria contained in drops 3, 4 and 5 decreased slowly and the concentration of bacteria was maintained above 9log CFU/mL, with the highest concentration of bacteria in drops 3.
The results of these experiments show that: compared with the single use of the sunflower seed oil and the olive oil or the combination of the sunflower seed oil and the olive oil and the peanut oil, the drop prepared by the combined use of the sunflower seed oil and the olive oil can show more excellent effect on improving the stability of probiotics.
Example 3 Effect of drops containing probiotic bacteria with addition of drying agent (drying agent) on the stability of probiotic bacteria
In this example, to see if the probiotic bacteria-containing drops of the present invention still have the above excellent effect and the desiccant further enhances the effect in the case of oxidation of fats and oils which may occur when the consumer contacts the air during daily use, the applicant carried out the following experiment on the MP108 drop 3 obtained in example 1 above and additionally prepared a drop with a desiccant for comparison.
The experimental method comprises the following steps:
first, a drop with a desiccant added (hereinafter referred to as drop 3-1) was prepared substantially according to the formulation of drop 3 shown in Table 2 above, and a dry tablet (obtained from Aptar CSP Technologies under the product model number M-3061-133ACTIVE TABLET,8.2mm (width) 17.7mm (length) 2.5mm (height) was additionally added.
Then, drop 3 and drop 3-1 were stored in a constant temperature and humidity machine set at 25 ℃ for 168 days, and during the storage period, the drops were exposed to air for 30 seconds each day to simulate the situation of use of the consumer, and 2mL of each of the 2 drops were diluted by adding 18mL of 0.1% peptone diluent before starting the storage (i.e., day 0) and at the 112 th, 140 th and 168 th days after starting the storage, followed by counting the number of bacteria in a plate count medium.
As a result:
table 3 below shows the change in bacterial concentration over time between drop 3 and drop 3-1 when stored at 25 ℃.
TABLE 3 bacterial concentrations of drops 3 and 3-1
As can be seen from table 3, both drop 3 and drop 3-1 contained bacteria at a count above 9.4log CFU/mL during storage over a period of 112 days to 168 days, and in particular, drop 3-1 maintained a bacterial concentration of 10log CFU/mL after storage over 168 days. The results of this experiment show that: the probiotic bacteria-containing drops of the present invention are still effective in maintaining the stability of the probiotic bacteria in daily use, and the addition of a drying agent to the probiotic bacteria-containing drops of the present invention can achieve better effectiveness.
Combining the above experimental results, the applicant believes that: the drop prepared by combining the sunflower seed oil and the olive oil can effectively improve the stability of probiotics, has the effect of maintaining the activity of the probiotics under long-term storage, and can further add a drying agent to achieve more remarkable excellent effect.
All patents and publications cited in this specification are herein incorporated by reference in their entirety. In case of conflict, the present detailed description, including definitions, will control.
While the invention has been described with reference to the specific embodiments described above, it will be apparent that many modifications and variations can be made without departing from the scope and spirit of the invention. It is the intention, therefore, to be limited only as indicated by the claims appended hereto.
Claims (6)
1. A probiotic drop, characterized by: the drops comprise, based on the total weight of the drops:
1-15wt% of probiotic bacteria;
31-50wt% sunflower seed oil;
31-50wt% olive oil; and
17-30wt% of triglyceride.
2. Probiotic drops according to claim 1, characterized in that: the sunflower oil has substantially the same content as olive oil.
3. Probiotic drops according to claim 1, characterized in that: said drops further comprising:
0.1-1.5wt% sucrose monoglyceride; and
0.01-0.05wt% of vitamin E.
4. Probiotic drops according to claim 1, characterized in that: the probiotic is selected from the group consisting of: lactobacillus spp, lactococcus spp, pediococcus spp, enterococcus spp, streptococcus spp, bifidobacterium spp, bacillus spp, leuconostoc spp and combinations thereof.
5. Probiotic drops according to claim 4, characterized in that: the probiotic is selected from the group consisting of: lactobacillus rhamnosus (Lactobacillus), bifidobacterium animalis subsp.
6. Probiotic drops according to claim 1, characterized in that: the drops further comprise a desiccant.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW110124079 | 2021-06-30 | ||
| TW110124079A TWI800860B (en) | 2021-06-30 | 2021-06-30 | Probiotic drop |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115531424A true CN115531424A (en) | 2022-12-30 |
Family
ID=84723012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110759489.0A Pending CN115531424A (en) | 2021-06-30 | 2021-07-05 | Probiotic drops |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115531424A (en) |
| TW (1) | TWI800860B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011016070A1 (en) * | 2009-08-06 | 2011-02-10 | Labomar S.R.L. | Nutraceutical compositions containing probiotics in an oily vehicle |
| CN105030843A (en) * | 2015-06-18 | 2015-11-11 | 陈英扬 | Lactobacillus reuteri drops and method for preparing same |
| CN107582573A (en) * | 2017-08-23 | 2018-01-16 | 江苏微康生物科技有限公司 | A kind of probiotics drops and preparation method thereof |
| CN112494529A (en) * | 2020-12-17 | 2021-03-16 | 拉格比(广东)健康科技有限公司 | Probiotic drop for improving intestinal colic and flatulence and preparation method thereof |
| CN112971145A (en) * | 2021-02-25 | 2021-06-18 | 谢驰南 | Probiotic drop and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11019838B2 (en) * | 2017-02-21 | 2021-06-01 | Jarrow Formulas, Inc. | Probiotic dietary supplement formulation |
-
2021
- 2021-06-30 TW TW110124079A patent/TWI800860B/en active
- 2021-07-05 CN CN202110759489.0A patent/CN115531424A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011016070A1 (en) * | 2009-08-06 | 2011-02-10 | Labomar S.R.L. | Nutraceutical compositions containing probiotics in an oily vehicle |
| CN105030843A (en) * | 2015-06-18 | 2015-11-11 | 陈英扬 | Lactobacillus reuteri drops and method for preparing same |
| CN107582573A (en) * | 2017-08-23 | 2018-01-16 | 江苏微康生物科技有限公司 | A kind of probiotics drops and preparation method thereof |
| CN112494529A (en) * | 2020-12-17 | 2021-03-16 | 拉格比(广东)健康科技有限公司 | Probiotic drop for improving intestinal colic and flatulence and preparation method thereof |
| CN112971145A (en) * | 2021-02-25 | 2021-06-18 | 谢驰南 | Probiotic drop and preparation method thereof |
Non-Patent Citations (6)
| Title |
|---|
| EA GARCIA: "New insights into the molecular effects and probiotic properties of Lactobacillus pentosus pre-adapted to edible oils", LWT, 10 April 2019 (2019-04-10), pages 153 - 162 * |
| PEREZ-BURILLO S: "Potential probiotic salami with dietary fiber modulates metabolism and gut microbiota in a human intervention study", JOURNAL OF FUNCTIONAL FOODS, 31 December 2020 (2020-12-31), pages 103790 * |
| 孙文轩: "基于三层高精度滴头制备一种胃肠道耐受型益生菌菌珠的研究", 科技创新导报, 9 September 2022 (2022-09-09), pages 11 - 17 * |
| 庾庆华: "益生菌制剂产品质量的关键因素探究", 现代食品, 15 August 2022 (2022-08-15), pages 128 - 132 * |
| 张金燕: "食物存放的安全常识", 食品与健康, 5 October 2013 (2013-10-05), pages 18 - 19 * |
| 颜姜瑜: "婴幼儿益生菌食品的应用现状及发展前景", 广东化工, 15 October 2018 (2018-10-15), pages 159 - 160 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202302126A (en) | 2023-01-16 |
| TWI800860B (en) | 2023-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102858948B (en) | There is the lactobacillus of antioxygenation | |
| JP5314421B2 (en) | Culture method of lactic acid bacteria with high immunomodulating activity | |
| JP7228533B2 (en) | Method for Producing Bacterial Compositions Comprising Biofilms with Beneficial Bacteria | |
| EP2717890A1 (en) | Spray-dried lactobacillus stems / cells and the use of same against helicobacter pylori | |
| US20230323332A1 (en) | Microencapsulation of microbial culture using octenyl succinic anhydride starch-chitosan complex coacervate | |
| WO2009010369A1 (en) | Food product comprising bacteria and sorbitan fatty acid | |
| CN107365705A (en) | A kind of oil-soluble probiotics freezes freeze drying protectant and its application of bacterium powder | |
| CN101357143A (en) | Probiotics powder composition and product thereof | |
| Chae et al. | Anti-inflammatory and anti-pathogenic potential of Lacticaseibacillus rhamnosus IDCC 3201 isolated from feces of breast-fed infants | |
| Kantachote et al. | Characterization of the antiyeast compound and probiotic properties of a starter Lactobacillus plantarum DW3 for possible use in fermented plant beverages | |
| CN115531424A (en) | Probiotic drops | |
| WO2023094649A1 (en) | Improved stability of microbial compositions, and manufacturing methods therefore | |
| Tian et al. | Effect of freeze-dried protectants on the survival rate and fermentation performance of fermented milk's directed vat set starters | |
| Ivanuša et al. | Probiotics and prebiotics in arterial hypertension | |
| JP5980785B2 (en) | New bifidobacteria and their use | |
| RU2795965C1 (en) | Method for manufacturing encapsulated form of a probiotic food supplement | |
| US11999944B2 (en) | Method for promoting growth of probiotic microorganism | |
| Ghasemi et al. | Evaluation of the prebiotic effects of fibers from pineapple, pomegranate and wheat by-products in synbiotic yoghurt containing probiotic Lactobacillus acidophilus La-5 bacterium. | |
| US20230100778A1 (en) | Method for promoting growth of probiotic microorganism | |
| US20240050493A1 (en) | Strains, compositions and methods of use | |
| WO2023094653A1 (en) | Fat and wax microencapsulated ambient stable bacteria and probiotics | |
| WO2023094652A1 (en) | Compositions for increased stability of bacteria | |
| AU2022398127A1 (en) | Fat and wax microencapsulated ambient stable bacteria and probiotics | |
| AU2022395766A1 (en) | Compositions for increased stability of bacteria | |
| Nguyen et al. | The Effect of a Glutathione (GSH)-Containing Cryo-Protectant on the Viability of Probiotic Cells Using a Freeze-Drying Process. Fermentation 2023, 9, 187 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |